ACXP Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. (ACXP) is expected to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is a loss of $0.45 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.9% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.